Published: 13 January 2015
Author(s): Mirjana Kovac, Zeljko Kovac, Zorica Tomasevic, Slavko Vucicevic, Valentina Djordjevic, Iva Pruner, Dragica Radojkovic
Section: Original Article

Estimates of the risk ratio of tamoxifen-associated venous thromboembolism (VTE) in breast cancer patients range from 2.4 to 7.1. The occurrence of thrombosis in patients with breast cancer complicates the clinical condition and causes a change of treatment. Our study was conducted in order to investigate the influence of patient-related risk factors for thrombosis development in breast cancer patients whose treatment included adjuvant tamoxifen.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.